Opinion
Video
Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer
Experts discuss evolving strategies in ER+/HER2– metastatic breast cancer treatment, combining endocrine and targeted therapies, and leveraging specific mutations for optimal patient outcomes.
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones leads a panel discussion on advances in therapy for estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer. Gradishar underscores the evolving treatment landscape, emphasizing the combination of endocrine and targeted therapies while considering specific mutations.
Vidal focuses on selective estrogen receptor degraders (SERDs), explaining their distinct mechanism compared with other anti-estrogen therapies. SERDs bind to receptors, facilitating their degradation and offering a unique approach. Vidal also mentions combination therapies with CDK4/6 inhibitors as part of targeted therapy strategies.
This expert dialogue provides crucial insights into the latest developments, particularly the role of oral SERDs, guiding clinicians in the dynamic field of metastatic breast cancer treatment.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
